ReviewEcancermedicalscience2019
Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update.
Review in Ecancermedicalscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- A mixed studies systematic review of the unmet treatment, support, and information needs of cancer survivors in managing menopause symptoms.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Trial
- Psychometric evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL questionnaire in women experiencing vasomotor symptoms associated with menopause.Journal of patient-reported outcomes · 2025Trial
- Efficacy of Herbal Remedies in Menopause: Bridging Traditional Medicine and Modern Therapeutics.Current drug research reviews · 2026Review
- Clinical practice guidelines: sexual dysfunction in gynecological cancer patients.Sexual medicine · 2025Review
- Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.Journal of patient-reported outcomes · 2025Article
- Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.Frontiers in reproductive health · 2025Review
- Article
- Exosome Therapy: A Novel Approach for Enhancing Estrogen Levels in Perimenopause.International journal of molecular sciences · 2024Article
- Insomnia in Postmenopausal Women: How to Approach and Treat It?Journal of clinical medicine · 2024Review
- Review
- Effect of a telehealth-based exercise intervention on the physical activity of patients with breast cancer: A systematic review and meta-analysis.Asia-Pacific journal of oncology nursing · 2022Review
- Hot flushes and sweating, sleep problems, joint and muscular discomfort, and physical and mental exhaustion in breast cancer survivors during the first 24 months of tamoxifen therapy: a prospective observational study.Frontiers in oncology · 2022Article
- Menopausal Hormone Therapy: a Comprehensive Review.Current atherosclerosis reports · 2020Review
- Prescription of hormone replacement therapy prior to and after the diagnosis of gynecological cancers in German patients.Journal of cancer research and clinical oncology · 2020Article
- Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal management of HFs requires a personalised approach to identify the treatment with the best benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens. Since isoflavones have oestrogenic properties and it is not known if they can be safely consumed by women with previous hormone-dependent cancer, they were excluded. Selective serotonin reuptake inhibitors/selective serotonin-norepinephrine reuptake inhibitors, as well as other neuroactive agents, some herbal remedies and behavioural strategies are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.